Recent developments include FDA clearance and launch of the Synchrony system, expanding the company’s digital surgery offerings, and reporting of Q4 2025 financial results showing a net loss. The company continues to advance its product portfolio and regulatory approvals.

• Stereotaxis received FDA clearance for the Synchrony system and announced its commercial launch in April 2026, expanding digital surgery capabilities in robotic and non-robotic cath labs [N1][N2][N3].
• The company reported a net loss for Q4 2025 and full-year 2025, with financial results reflecting ongoing investment in product development and commercialization [N5][N6].
• Stereotaxis continues to pursue regulatory approvals for its products globally and to develop next-generation imaging and collaboration solutions [N1][N2].
• The acquisition of Access Point Technologies EP, Inc. in 2024 added catheter development and manufacturing expertise to support innovation [S2].

Stereotaxis’ recent FDA clearance and launch of the Synchrony system represent a significant advancement in its digital surgery offerings, potentially enhancing procedure efficiency and user experience. The GenesisX RMN System’s design to reduce installation time may lower barriers to adoption. The acquisition of Access Point Technologies EP, Inc. adds in-house catheter development expertise, supporting innovation and product pipeline expansion. The company’s strategic relationships and regulatory approvals across multiple geographies provide a foundation for commercial growth. The growing clinical acceptance of robotic magnetic navigation in electrophysiology and aspirations to expand into other endovascular indications could broaden market opportunities.

The company reported a net loss of $21.6 million in 2025, reflecting ongoing challenges in achieving profitability. Macroeconomic pressures, including supply chain disruptions, inflation, tariffs, and hospital capital constraints, pose risks to sales cycles and disposable product demand. The capital-intensive nature of system sales and long installation cycles may delay revenue recognition. Regulatory approval processes remain lengthy and uncertain, potentially delaying product launches. Competition from larger medical device companies and the need to maintain strategic partnerships add to execution risks. Liquidity, while moderate, requires ongoing management to support operations and development.

Stereotaxis’ moat is anchored in its proprietary Robotic Magnetic Navigation technology, which offers a unique method of catheter control via computer-controlled magnetic fields, differentiating it from manual catheter navigation. The technology’s clinical adoption is supported by substantial real-world evidence, including over 150,000 treated patients and more than 500 clinical publications, which underpin its safety and efficacy claims. Strategic partnerships with fluoroscopy system manufacturers and electrophysiology mapping providers enhance product integration and customer value. The company’s regulatory clearances across major markets and its expanding product portfolio, including next-generation systems and digital surgery solutions, contribute to its competitive positioning. However, the niche focus on electrophysiology and the capital-intensive nature of its systems may limit rapid market penetration, and the company faces competition from established medical device firms.

• Macroeconomic and Supply Chain Risks: The company faces risks from inflation, tariffs, supply chain disruptions, and geopolitical factors that could increase costs and delay product availability [S2].
• Hospital Customer Capital Constraints: Hospitals’ financial pressures and capital spending challenges may delay or reduce orders for robotic systems and disposable products, impacting revenue [S2].
• Regulatory Approval Uncertainty: Lengthy and uncertain regulatory approval processes could delay product launches and market expansion [S2].
• Competitive Pressure: Competition from established medical device companies and the need to maintain strategic partnerships pose risks to market share and product integration [S2].
• Profitability and Liquidity: The company reported net losses and must manage liquidity carefully to fund operations and development without guaranteed access to capital markets [S1][S2].

• Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory, primarily focused on electrophysiology and cardiac ablation procedures for arrhythmias [S2].
• The company’s proprietary technology, Robotic Magnetic Navigation (RMN), uses computer-controlled magnetic fields to precisely control the tip of flexible interventional catheters, improving precision, stability, reach, and safety during procedures [S2].
• Primary products include the Genesis RMN System, GenesisX RMN System (latest generation), Odyssey Solution, and related devices [S2].
• The Genesis RMN System enables image-guided delivery of catheters through blood vessels and heart chambers, improving navigation and reducing x-ray exposure [S2].
• The GenesisX RMN System enhances accessibility by eliminating lengthy installation cycles required by prior generation systems [S2].
• The Odyssey Solution consolidates lab information on a large integrated display to improve lab layout and procedure efficiency; it is being replaced by next-generation solutions branded Synchrony and SynX [S2].
• Synchrony is a 4K ultra-high-definition display system that digitizes and modernizes the interventional cath lab, offering custom layouts, streamlined workflows, and an intuitive interface [S2].
• SynX is a cloud-based HIPAA and GDPR-compliant app enabling secure remote connectivity, collaboration, recording, and monitoring of the cath lab [S2].
• Stereotaxis has strategic relationships with fluoroscopy system manufacturers, catheter providers, and electrophysiology mapping system providers to offer integrated x-ray systems and accessory devices [S2].
• The company’s business model includes upfront capital sales of systems and recurring revenue from proprietary disposable devices, royalties from co-development/co-placement arrangements, and ongoing software updates and service contracts [S2].
• Revenue recognition follows ASC 606, with multiple performance obligations in system sales contracts, including delivery, installation, service warranties, and software enhancements [S2].
• The company’s products have regulatory clearances in the U.S., Europe, China, Canada, and Japan, with ongoing efforts to expand approvals globally [S2].
• Recent FDA clearance and launch of the Synchrony system, a next-generation digital surgery solution, was announced in April 2026 [N1][N2][N3].
• The company completed acquisition of Access Point Technologies EP, Inc. (APT) in July 2024, adding in-house catheter development and manufacturing expertise [S2].
• Stereotaxis reported a net loss of $21.6 million for fiscal year ended December 31, 2025, with basic and diluted EPS of -$0.25 [S1].
• As of December 31, 2025, the company had $13.4 million in cash and cash equivalents, current assets of $33.8 million, current liabilities of $22.4 million, a current ratio of 1.51, and a cash ratio of 0.6 [S1].
• The company had no debt as of the latest filings [S2].
• The company faces risks from macroeconomic factors including supply chain disruptions, tariffs, inflation, and hospital customer capital constraints that may delay orders or reduce demand [S2].
• The company’s revenue mix includes system sales, disposable interventional devices, service, and accessories, with gross margin improvements driven by product mix changes [S2].
• The company’s robotic magnetic navigation technology has been used by hundreds of electrophysiologists at over 100 hospitals globally, treating over 150,000 arrhythmia patients, supported by over 500 clinical publications [S2].